Farther Finance Advisors, LLC Viridian Therapeutics, Inc.\De Transaction History
Farther Finance Advisors, LLC
- $5 Trillion
- Q2 2025
A detailed history of Farther Finance Advisors, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 449 shares of VRDN stock, worth $7,655. This represents 0.0% of its overall portfolio holdings.
Number of Shares
449
Previous 1
44800.0%
Holding current value
$7,655
Previous $13,000
48184.62%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding VRDN
# of Institutions
188Shares Held
79.6MCall Options Held
92.2KPut Options Held
55.2K-
Deep Track Capital, LP Greenwich, CT5.38MShares$91.7 Million2.54% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$81.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.7MShares$80.1 Million5.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.56MShares$77.8 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$66.2 Million12.64% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $680M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...